Research programme: immuno-oncology therapeutics - Cue Biopharma

Drug Profile

Research programme: immuno-oncology therapeutics - Cue Biopharma

Alternative Names: CUE 101; CUE 102; Immuno-STAT™

Latest Information Update: 23 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cue Biopharma
  • Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action CD27 antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Cancer

Most Recent Events

  • 16 Nov 2017 Cue Biopharma and Merck agree to develop immuno-oncology therapeutics for Autoimmune disorders
  • 06 Apr 2017 Immuno-oncology therapeutics - Cue Biopharma is available for licensing as of 01 Mar 2017.
  • 03 Mar 2017 Cue Biopharma intends to file an IND application for CUE 101 and CUE 102 for Cancer in 2017 (Cue Biopharma pipeline, March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top